Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.

The renal handling of cis-diamminedichloroplatinum (CP) was investigated by measuring the renal clearance of creatinine, inulin, and free platinum in ten cancer patients. Free platinum clearances exceeded the glomerular filtration rate in all time periods. For example, at 1 to 2 hr, the mean clearance of free platinum was 224 +/- 32 (S.E.) ml/min compared to a mean creatinine clearance of 94 +/- 15 ml/min or a mean inulin clearance of 94 +/- 17 ml/min (p less than 0.01), indicating secretion of CP or a metabolite. Seven additional cancer patients were treated with probenecid prior to CP. Fractional platinum clearances, calculated as a ratio of free platinum clearance to creatinine clearance, were reduced significantly in the probenecid-treated group (158 +/- 17%) compared to controls (270 +/- 57%) (p less than 0.03). Fractional platinum clearances, calculated as a ratio of free platinum clearance to inulin clearance, were also significantly reduced in the treated group (154 +/- 14%) compared to controls (271 +/- 47%) (p = 0.04). These results suggest that cisplatin is secreted by the human kidney, and this can be inhibited by probenecid. Such maneuvers may be helpful in improving the therapeutic index of this important chemotherapeutic agent.

[1]  P. Daley-Yates,et al.  Cisplatin metabolites: a method for their separation and for measurement of their renal clearance in vivo. , 1983, Biochemical pharmacology.

[2]  S. Lippard New chemistry of an old molecule: cis-[Pt(NH3)2Cl2]. , 1982, Science.

[3]  R. Safirstein,et al.  Renal transport and biotransformation of cisplatin (P) , 1982 .

[4]  N. Martini,et al.  Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. , 1981, Annals of internal medicine.

[5]  B. Rennick Renal tubule transport of organic cations. , 1981, The American journal of physiology.

[6]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.

[7]  M. Weiner,et al.  Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. , 1980, The Journal of pharmacology and experimental therapeutics.

[8]  M. Weiner,et al.  Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. , 1980, The Journal of pharmacology and experimental therapeutics.

[9]  L. Einhorn,et al.  Long term effect of Cis‐Diamminedichloride platinum (CDDP) on renal function and structure in man , 1978, Cancer.

[10]  D. V. Von Hoff,et al.  Cis-diamminedichloroplatinum (II). A new anticancer drug. , 1977, Annals of internal medicine.

[11]  R. Lange,et al.  Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). , 1973, Cancer research.

[12]  T. Stamey,et al.  Adapted method for determination of inulin in serum and urine with an AutoAnalyzer. , 1968, The Journal of laboratory and clinical medicine.

[13]  G. Mudge,et al.  RENAL TUBULAR MECHANISMS FOR EXCRETION OF ORGANIC ACIDS AND BASES. , 1964, The American journal of medicine.

[14]  R. B. Harvey,et al.  RENAL EXTRACTION OF PARA‐AMINOHIPPURATE AND CREATININE MEASURED BY CONTINUOUS IN VIVO SAMPLING OF ARTERIAL AND RENAL‐VEIN BLOOD , 1962, Annals of the New York Academy of Sciences.